Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT
Purpose 4′-[Methyl-11C] thiothymidine (4DST) incorporates into DNA directly and is a PET tracer used for cell proliferation imaging. The aim of this study was to evaluate the prediction of prognosis with pretreatment 4DST PET/CT compared to fluorodeoxyglucose (FDG) PET/CT in patients with esophageal...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2021-07, Vol.48 (8), p.2615-2623 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2623 |
|---|---|
| container_issue | 8 |
| container_start_page | 2615 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 48 |
| creator | Hotta, Masatoshi Minamimoto, Ryogo Toyohara, Jun Nohara, Kyoko Nakajima, Kazuhiko Takase, Kei Yamada, Kazuhiko |
| description | Purpose
4′-[Methyl-11C] thiothymidine (4DST) incorporates into DNA directly and is a PET tracer used for cell proliferation imaging. The aim of this study was to evaluate the prediction of prognosis with pretreatment 4DST PET/CT compared to fluorodeoxyglucose (FDG) PET/CT in patients with esophageal cancer.
Methods
In this prospective study, we analyzed 46 patients (68.2 ± 10.0 years old) with pathologically proven esophageal squamous cell cancer who underwent pretreatment 4DST and FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion proliferation (TLP) were measured for FDG and 4DST PET. The study endpoints were progression-free survival (PFS) and overall survival (OS). Patients’ clinical backgrounds, including age, histological type, clinical stage, and surgical treatment, were adjusted using the Cox proportional-hazards model.
Results
In the follow-up period (median 18.8 (interquartile range: 10.1–29.0) months), 26 and 19 patients showed disease progression and cancer-related death, respectively. After adjusting for clinical variables, only the 4DST parameters (SUVmax (
p
= 0.001) and TLP (
p
= 0.022)) were statistically significant for predicting PFS. FDG MTV (
p
= 0.031), 4DST SUVmax (
p
= 0.022), and TLP (
p
= 0.023) were statistically significant for predicting OS. Of the PET parameters, 4DST SUVmax yielded the highest adjusted hazard ratio for both PFS (4.88, 95% confidence intervals (CI): 1.83–12.97) and OS (4.19, 95% CI: 1.23–14.20).
Conclusion
Higher accumulation of 4DST in the primary tumor may lead to shorter OS and PFS. 4DST PET/CT is useful for predicting prognosis and may outperform FDG PET/CT. |
| doi_str_mv | 10.1007/s00259-020-05179-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2477513151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2546405719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-274fb3e303dc393aa073d3a2a7d714801548606a53120a202dfddb163197b0a83</originalsourceid><addsrcrecordid>eNp9kc1O3DAUha0KVGDaF-iistRNN4FrO4kTdtUwUCQkKnW6tjz-yRhl4mAngnmWvixOM6VSFywsW7rfOff6HoQ-ETgnAPwiAtCizoBCBgXhdfb8Dp2SktQZh6o-en1zOEFnMT4AkIpW9Xt0wljOquRxin6vrHVKqj32FivTtrgPvnXWBDk432G3k43rGvzkhi3Or36u8Y_V-mK5xtaHhBrt1DDVh62ZlE3no4uTV5_0phvirDTR91vZGNliJTtlwiWWWPldL4OLqU0cRr2f0eurm0OPD-jYyjaaj4d7gX5dr9bL79nd_c3t8ttdphgvhozy3G6YYcC0YjWTEjjTTFLJNSd5BaTIqxJKWTBCQVKg2mq9ISUjNd-ArNgCfZ190wceRxMHsXNx2oXsjB-joDnnBWEknQX68h_64MfQpekELfIyh4KTOlF0plTwMQZjRR_SIsNeEBBTdGKOTqToxJ_oxHMSfT5Yj5ud0a-Sv1klgM1ATKWuMeFf7zdsXwBB9qPf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546405719</pqid></control><display><type>article</type><title>Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hotta, Masatoshi ; Minamimoto, Ryogo ; Toyohara, Jun ; Nohara, Kyoko ; Nakajima, Kazuhiko ; Takase, Kei ; Yamada, Kazuhiko</creator><creatorcontrib>Hotta, Masatoshi ; Minamimoto, Ryogo ; Toyohara, Jun ; Nohara, Kyoko ; Nakajima, Kazuhiko ; Takase, Kei ; Yamada, Kazuhiko</creatorcontrib><description>Purpose
4′-[Methyl-11C] thiothymidine (4DST) incorporates into DNA directly and is a PET tracer used for cell proliferation imaging. The aim of this study was to evaluate the prediction of prognosis with pretreatment 4DST PET/CT compared to fluorodeoxyglucose (FDG) PET/CT in patients with esophageal cancer.
Methods
In this prospective study, we analyzed 46 patients (68.2 ± 10.0 years old) with pathologically proven esophageal squamous cell cancer who underwent pretreatment 4DST and FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion proliferation (TLP) were measured for FDG and 4DST PET. The study endpoints were progression-free survival (PFS) and overall survival (OS). Patients’ clinical backgrounds, including age, histological type, clinical stage, and surgical treatment, were adjusted using the Cox proportional-hazards model.
Results
In the follow-up period (median 18.8 (interquartile range: 10.1–29.0) months), 26 and 19 patients showed disease progression and cancer-related death, respectively. After adjusting for clinical variables, only the 4DST parameters (SUVmax (
p
= 0.001) and TLP (
p
= 0.022)) were statistically significant for predicting PFS. FDG MTV (
p
= 0.031), 4DST SUVmax (
p
= 0.022), and TLP (
p
= 0.023) were statistically significant for predicting OS. Of the PET parameters, 4DST SUVmax yielded the highest adjusted hazard ratio for both PFS (4.88, 95% confidence intervals (CI): 1.83–12.97) and OS (4.19, 95% CI: 1.23–14.20).
Conclusion
Higher accumulation of 4DST in the primary tumor may lead to shorter OS and PFS. 4DST PET/CT is useful for predicting prognosis and may outperform FDG PET/CT.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-020-05179-x</identifier><identifier>PMID: 33438100</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Cancer ; Cardiology ; Cell growth ; Cell Proliferation ; Computed tomography ; Confidence intervals ; Esophageal cancer ; Esophageal Neoplasms - diagnostic imaging ; Esophagus ; Fluorodeoxyglucose F18 ; Glycolysis ; Humans ; Imaging ; Medical imaging ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Nuclear Medicine ; Oncology ; Oncology – Digestive tract ; Original Article ; Orthopedics ; Parameters ; Patients ; Positron emission ; Positron emission tomography ; Positron Emission Tomography Computed Tomography ; Pretreatment ; Prognosis ; Prospective Studies ; Radiology ; Retrospective Studies ; Statistical analysis ; Survival ; Tomography ; Tumor Burden ; Tumors</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2021-07, Vol.48 (8), p.2615-2623</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-274fb3e303dc393aa073d3a2a7d714801548606a53120a202dfddb163197b0a83</citedby><cites>FETCH-LOGICAL-c375t-274fb3e303dc393aa073d3a2a7d714801548606a53120a202dfddb163197b0a83</cites><orcidid>0000-0001-6790-8804</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-020-05179-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-020-05179-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33438100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hotta, Masatoshi</creatorcontrib><creatorcontrib>Minamimoto, Ryogo</creatorcontrib><creatorcontrib>Toyohara, Jun</creatorcontrib><creatorcontrib>Nohara, Kyoko</creatorcontrib><creatorcontrib>Nakajima, Kazuhiko</creatorcontrib><creatorcontrib>Takase, Kei</creatorcontrib><creatorcontrib>Yamada, Kazuhiko</creatorcontrib><title>Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
4′-[Methyl-11C] thiothymidine (4DST) incorporates into DNA directly and is a PET tracer used for cell proliferation imaging. The aim of this study was to evaluate the prediction of prognosis with pretreatment 4DST PET/CT compared to fluorodeoxyglucose (FDG) PET/CT in patients with esophageal cancer.
Methods
In this prospective study, we analyzed 46 patients (68.2 ± 10.0 years old) with pathologically proven esophageal squamous cell cancer who underwent pretreatment 4DST and FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion proliferation (TLP) were measured for FDG and 4DST PET. The study endpoints were progression-free survival (PFS) and overall survival (OS). Patients’ clinical backgrounds, including age, histological type, clinical stage, and surgical treatment, were adjusted using the Cox proportional-hazards model.
Results
In the follow-up period (median 18.8 (interquartile range: 10.1–29.0) months), 26 and 19 patients showed disease progression and cancer-related death, respectively. After adjusting for clinical variables, only the 4DST parameters (SUVmax (
p
= 0.001) and TLP (
p
= 0.022)) were statistically significant for predicting PFS. FDG MTV (
p
= 0.031), 4DST SUVmax (
p
= 0.022), and TLP (
p
= 0.023) were statistically significant for predicting OS. Of the PET parameters, 4DST SUVmax yielded the highest adjusted hazard ratio for both PFS (4.88, 95% confidence intervals (CI): 1.83–12.97) and OS (4.19, 95% CI: 1.23–14.20).
Conclusion
Higher accumulation of 4DST in the primary tumor may lead to shorter OS and PFS. 4DST PET/CT is useful for predicting prognosis and may outperform FDG PET/CT.</description><subject>Aged</subject><subject>Cancer</subject><subject>Cardiology</subject><subject>Cell growth</subject><subject>Cell Proliferation</subject><subject>Computed tomography</subject><subject>Confidence intervals</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - diagnostic imaging</subject><subject>Esophagus</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glycolysis</subject><subject>Humans</subject><subject>Imaging</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – Digestive tract</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Parameters</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Pretreatment</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Radiology</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Tomography</subject><subject>Tumor Burden</subject><subject>Tumors</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1O3DAUha0KVGDaF-iistRNN4FrO4kTdtUwUCQkKnW6tjz-yRhl4mAngnmWvixOM6VSFywsW7rfOff6HoQ-ETgnAPwiAtCizoBCBgXhdfb8Dp2SktQZh6o-en1zOEFnMT4AkIpW9Xt0wljOquRxin6vrHVKqj32FivTtrgPvnXWBDk432G3k43rGvzkhi3Or36u8Y_V-mK5xtaHhBrt1DDVh62ZlE3no4uTV5_0phvirDTR91vZGNliJTtlwiWWWPldL4OLqU0cRr2f0eurm0OPD-jYyjaaj4d7gX5dr9bL79nd_c3t8ttdphgvhozy3G6YYcC0YjWTEjjTTFLJNSd5BaTIqxJKWTBCQVKg2mq9ISUjNd-ArNgCfZ190wceRxMHsXNx2oXsjB-joDnnBWEknQX68h_64MfQpekELfIyh4KTOlF0plTwMQZjRR_SIsNeEBBTdGKOTqToxJ_oxHMSfT5Yj5ud0a-Sv1klgM1ATKWuMeFf7zdsXwBB9qPf</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Hotta, Masatoshi</creator><creator>Minamimoto, Ryogo</creator><creator>Toyohara, Jun</creator><creator>Nohara, Kyoko</creator><creator>Nakajima, Kazuhiko</creator><creator>Takase, Kei</creator><creator>Yamada, Kazuhiko</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6790-8804</orcidid></search><sort><creationdate>20210701</creationdate><title>Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT</title><author>Hotta, Masatoshi ; Minamimoto, Ryogo ; Toyohara, Jun ; Nohara, Kyoko ; Nakajima, Kazuhiko ; Takase, Kei ; Yamada, Kazuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-274fb3e303dc393aa073d3a2a7d714801548606a53120a202dfddb163197b0a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Cancer</topic><topic>Cardiology</topic><topic>Cell growth</topic><topic>Cell Proliferation</topic><topic>Computed tomography</topic><topic>Confidence intervals</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - diagnostic imaging</topic><topic>Esophagus</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glycolysis</topic><topic>Humans</topic><topic>Imaging</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – Digestive tract</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Parameters</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Pretreatment</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Radiology</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Tomography</topic><topic>Tumor Burden</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hotta, Masatoshi</creatorcontrib><creatorcontrib>Minamimoto, Ryogo</creatorcontrib><creatorcontrib>Toyohara, Jun</creatorcontrib><creatorcontrib>Nohara, Kyoko</creatorcontrib><creatorcontrib>Nakajima, Kazuhiko</creatorcontrib><creatorcontrib>Takase, Kei</creatorcontrib><creatorcontrib>Yamada, Kazuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hotta, Masatoshi</au><au>Minamimoto, Ryogo</au><au>Toyohara, Jun</au><au>Nohara, Kyoko</au><au>Nakajima, Kazuhiko</au><au>Takase, Kei</au><au>Yamada, Kazuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>48</volume><issue>8</issue><spage>2615</spage><epage>2623</epage><pages>2615-2623</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
4′-[Methyl-11C] thiothymidine (4DST) incorporates into DNA directly and is a PET tracer used for cell proliferation imaging. The aim of this study was to evaluate the prediction of prognosis with pretreatment 4DST PET/CT compared to fluorodeoxyglucose (FDG) PET/CT in patients with esophageal cancer.
Methods
In this prospective study, we analyzed 46 patients (68.2 ± 10.0 years old) with pathologically proven esophageal squamous cell cancer who underwent pretreatment 4DST and FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion proliferation (TLP) were measured for FDG and 4DST PET. The study endpoints were progression-free survival (PFS) and overall survival (OS). Patients’ clinical backgrounds, including age, histological type, clinical stage, and surgical treatment, were adjusted using the Cox proportional-hazards model.
Results
In the follow-up period (median 18.8 (interquartile range: 10.1–29.0) months), 26 and 19 patients showed disease progression and cancer-related death, respectively. After adjusting for clinical variables, only the 4DST parameters (SUVmax (
p
= 0.001) and TLP (
p
= 0.022)) were statistically significant for predicting PFS. FDG MTV (
p
= 0.031), 4DST SUVmax (
p
= 0.022), and TLP (
p
= 0.023) were statistically significant for predicting OS. Of the PET parameters, 4DST SUVmax yielded the highest adjusted hazard ratio for both PFS (4.88, 95% confidence intervals (CI): 1.83–12.97) and OS (4.19, 95% CI: 1.23–14.20).
Conclusion
Higher accumulation of 4DST in the primary tumor may lead to shorter OS and PFS. 4DST PET/CT is useful for predicting prognosis and may outperform FDG PET/CT.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33438100</pmid><doi>10.1007/s00259-020-05179-x</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6790-8804</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2021-07, Vol.48 (8), p.2615-2623 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2477513151 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Cancer Cardiology Cell growth Cell Proliferation Computed tomography Confidence intervals Esophageal cancer Esophageal Neoplasms - diagnostic imaging Esophagus Fluorodeoxyglucose F18 Glycolysis Humans Imaging Medical imaging Medical prognosis Medicine Medicine & Public Health Middle Aged Nuclear Medicine Oncology Oncology – Digestive tract Original Article Orthopedics Parameters Patients Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography Pretreatment Prognosis Prospective Studies Radiology Retrospective Studies Statistical analysis Survival Tomography Tumor Burden Tumors |
| title | Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T01%3A47%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20cell%20proliferation%20imaging%20with%204DST%20PET/CT%20for%20predicting%20the%20prognosis%20of%20patients%20with%20esophageal%20cancer:%20a%20comparison%20study%20with%20FDG%20PET/CT&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Hotta,%20Masatoshi&rft.date=2021-07-01&rft.volume=48&rft.issue=8&rft.spage=2615&rft.epage=2623&rft.pages=2615-2623&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-020-05179-x&rft_dat=%3Cproquest_cross%3E2546405719%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2546405719&rft_id=info:pmid/33438100&rfr_iscdi=true |